Cannabinoids and Vanilloids in Schizophrenia: Neurophysiological Evidence and Directions for Basic Research
Rafael Naime Ruggiero, Matheus Teixeira Rossignoli, Jana Batista de Ross, Jaime E. C. Hallak, João Pereira Leite, Lézio Soares Bueno-Júnior
Frontiers in Pharmacology June 21, 2017 DOI: 10.3389/fphar.2017.00399 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Cannabis CBD |
| Keywords | Schizophrenia object-oriented programming Prepulse inhibition Endocannabinoid system Neurophysiology Neurochemical Sensory gating Psychosis Glutamatergic Glutamate receptor |
| Citations | 37 |
| Key findings | Greater use of neurophysiological tools like electrophysiology and optogenetics is needed to clarify how exogenous cannabinoids affect schizophrenia symptoms. |
Abstract
Much of our knowledge of the endocannabinoid system in schizophrenia comes from behavioral measures in rodents, like prepulse inhibition of the acoustic startle and open-field locomotion, which are commonly used along with neurochemical approaches or drug challenge designs. Such methods continue to map fundamental mechanisms of sensorimotor gating, hyperlocomotion, social interaction, and underlying monoaminergic, glutamatergic, and GABAergic disturbances. These strategies will require, however, a greater use of neurophysiological tools to better inform clinical research. In this sense, electrophysiology and viral vector-based circuit dissection, like optogenetics, can further elucidate how exogenous cannabinoids worsen (e.g., tetrahydrocannabinol, THC) or ameliorate (e.g., cannabidiol, CBD) schizophrenia symptoms, like hallucinations, delusions, and cognitive deficits. Also, recent studies point to a complex endocannabinoid-endovanilloid interplay, including the influence of anandamide (endogenous CB 1 and TRPV 1 agonist) on cognitive variables, such as aversive memory extinction. In fact, growing interest has been devoted to TRPV 1 receptors as promising therapeutic targets. Here, these issues are reviewed with an emphasis on the neurophysiological evidence. First, we contextualize imaging and electrographic findings in humans. Then, we present a comprehensive review on rodent electrophysiology. Finally, we discuss how basic research will benefit from further combining psychopharmacological and neurophysiological tools.
Comparable studies
Other narrative reviews on CBD, most cited first.
Citations in the library
Cited by 2
Cites 38
- Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans Archives of General Psychiatry March 1, 1994
- Recent advances in the phencyclidine model of schizophrenia American Journal of Psychiatry October 1, 1991
- Distinct Effects of Δ9-Tetrahydrocannabinol and Cannabidiol on Neural Activation During Emotional Processing Archives of General Psychiatry 2009
- Modulation of Mediotemporal and Ventrostriatal Function in Humans by Δ9-Tetrahydrocannabinol Archives of General Psychiatry April 1, 2009
- Disruption of Prefrontal Cortex Large Scale Neuronal Activity by Different Classes of Psychotomimetic Drugs Journal of Neuroscience February 29, 2012
and 33 more in the library